Genetic Mechanisms Driving Uterine Leiomyoma Pathobiology, Epidemiology, and Treatment
Genes · 27.04.2024 · 15 (5) · 558
DOI: 10.3390/genes15050558 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 27.04.2024. Verfasst von Malini S Ramaiyer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Hauptthemen laut MEDLINE: Leiomyoma, Uterine Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Uterine leiomyomas (ULs) are the most common benign tumor of the uterus. They can be associated with symptoms including abnormal uterine bleeding, pelvic pain, urinary frequency, and pregnancy complications. Despite the high prevalence of UL, its underlying pathophysiology mechanisms have historically been poorly understood. Several mechanisms of pathogenesis have been suggested, implicating various genes, growth factors, cytokines, chemokines, and microRNA aberrations. The purpose of this study is to summarize the current research on the relationship of genetics with UL. Specifically, we performed a literature review of published studies to identify how genetic aberrations drive pathophysiology, epidemiology, and therapeutic approaches of UL. With regards to pathophysiology, research has identified MED12 mutations, HMGA2 overexpression, fumarate hydratase deficiency, and cytogenetic abnormalities as contributors to the development of UL. Additionally, epigenetic modifications, such as histone acetylation and DNA methylation, have been identified as contributing to UL tumorigenesis. Specifically, UL stem cells have been found to contain a unique DNA methylation pattern compared to more differentiated UL cells, suggesting that DNA methylation has a role in tumorigenesis. On a population level, genome-wide association studies (GWASs) and epidemiologic analyses have identified 23 genetic loci associated with younger age at menarche and UL growth. Additionally, various GWASs have investigated genetic loci as potential drivers of racial disparities in UL incidence. For example, decreased expression of Cytohesin 4 in African Americans has been associated with increased UL risk. Recent studies have investigated various therapeutic options, including ten-eleven translocation proteins mediating DNA methylation, adenovirus vectors for drug delivery, and “suicide gene therapy” to induce apoptosis. Overall, improved understanding of the genetic and epigenetic drivers of UL on an individual and population level can propel the discovery of novel therapeutic options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
- Department of Gynecology and Obstetrics, Johns Hopkins University, 720 Rutland Ave, Baltimore, MD 21205, USA.
- Faculty of Medicine, Selcuk University, 42000 Konya, Turkey.
ORCID-Profile: Mostafa A Borahay
Förderung
- NICHD NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Ramaiyer, M. S., Saad, E., Kurt, I., & Borahay, M. A. (2024). Genetic Mechanisms Driving Uterine Leiomyoma Pathobiology, Epidemiology, and Treatment. Genes, 15(5), 558. https://doi.org/10.3390/genes15050558
Vancouver
Ramaiyer MS, Saad E, Kurt I, Borahay MA. Genetic Mechanisms Driving Uterine Leiomyoma Pathobiology, Epidemiology, and Treatment. Genes. 2024;15(5):558. doi:10.3390/genes15050558
BibTeX
@article{Ramaiyer2024,
author = {Ramaiyer, Malini S and Saad, Eslam and Kurt, Irem and Borahay, Mostafa A},
title = {Genetic Mechanisms Driving Uterine Leiomyoma Pathobiology, Epidemiology, and Treatment},
journal = {Genes},
year = {2024},
volume = {15},
number = {5},
pages = {558},
doi = {10.3390/genes15050558}
}
EUVIMED